Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mesoblast Limited ( (AU:MSB) ) has shared an update.
Mesoblast Limited has announced a webcast to discuss its operational highlights and financial results for the fiscal year ending June 30, 2025. The company continues to focus on expanding its cell therapy offerings, with ongoing developments in treatments for inflammatory diseases, heart failure, and chronic low back pain. Mesoblast’s strong intellectual property portfolio and proprietary manufacturing processes position it well for future growth and global market expansion.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$2.97 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for treating severe inflammatory diseases. The company utilizes its proprietary mesenchymal lineage cell therapy technology to create therapies that release anti-inflammatory factors, significantly reducing damaging inflammation. Mesoblast’s flagship product, Ryoncil, is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease. The company is also developing additional therapies for various inflammatory conditions and has established commercial partnerships in Japan, Europe, and China.
Average Trading Volume: 4,851,898
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.15B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.